Det nye forumet finner du her

Tilbake til: Farma og medisin
Innlegg av: Hyggelige (13.04.18 00:22 ), lest 1811 ganger
Ticker: TRVX

RE^1: TRVX - OPP 20% PÅ FÅ DAGER

Wheeler har nylig vært Chief Medical Officer i Acetylon Pharmaceutical og før det hatt lederstillinger i Roche, AstraZeneca og Parexel


Acetylon Pharmaceuticals, Inc. engages in the development of small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company’s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized Class I and Class II histone deacetylase selective compounds for oral administration. It offers ACY-1215 and ACY-241 lead drug candidates that are selective HDAC6 inhibitors currently in Phase 2 and Phase 1b clinical development for the treatment of multiple myeloma. Acetylon Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts. As of December 16, 2016, Acetylon Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=61842260